In mouse models of NASH, administration of a selective NLRP3 inhibitor suppressed caspase-1 and IL-1β accumulation, and limited the development of fibrosis [162], suggesting that the inflammasome plays a key role in mediating the progression of NAFLD. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.